復星醫藥(02196)產品治療高甘油三酯血症，獲准開展臨床試驗

　　復星醫藥(02196)(滬:600196)公布，控股子公司復星醫藥產業發展收到國家藥品監督管理局同意FXR0906注射液用於治療高甘油三酯血症開展臨床試驗的批准，擬於條件具備後於內地開展該藥物的I期臨床研究。

　　該集團指，截至6月，針對FXR0906的累計研發投入約7100萬元人民幣，而內地尚無用於治療高甘油三酯血症的小干擾核酸藥物獲批上市。
《經濟通通訊社16日專訊》

【你點睇？】政府公布白石角站項目推展模式，你是否支持白石角站附近用地改為全面興建私人住宅？ ► 立即投票

回頁頂

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。